Landos Biopharma, Inc.
NASDAQ:LABP
22.93 (USD) • At close May 23, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -18 | 0 | 18 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.224 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.224 | 0 | -18 | 0 | 18 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 3.151 | 3.147 | 3.063 | 2.463 | 3.326 | 3.414 | 4.862 | 6.604 | 10.8 | 13.444 | 9.344 | 11.522 | 7.254 | 9.959 | 6.966 | 3.723 | 4.69 | 3.357 |
| General & Administrative Expenses
| 6.144 | 3.463 | 2.136 | 1.976 | 3.153 | 3.099 | 2.967 | 4.662 | 4.153 | 6.952 | 3.059 | 2.596 | 2.646 | 1.44 | 1.453 | 1.365 | 1.08 | 0.381 |
| Selling & Marketing Expenses
| 0 | -0.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 6.144 | 3.163 | 2.136 | 1.976 | 3.153 | 3.099 | 2.967 | 4.662 | 4.153 | 6.952 | 3.059 | 2.596 | 2.646 | 1.44 | 1.453 | 1.365 | 1.08 | 0.381 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 1.281 | -0.067 | -0.043 | 0.088 | 0 | 0 | 0.041 | 0.064 | 0 | 0 | 0 | 0.197 | 0 |
| Operating Expenses
| 9.295 | 6.31 | 5.199 | 4.439 | 6.479 | 6.513 | 7.829 | 11.266 | 14.953 | 20.396 | 12.403 | 14.118 | 9.9 | 11.399 | 8.419 | 5.088 | 5.77 | 3.738 |
| Operating Income
| -9.295 | -6.31 | -5.199 | -4.439 | -6.479 | -6.513 | -7.829 | -11.266 | -14.953 | -20.396 | -12.403 | 3.882 | -9.9 | -11.399 | -8.419 | -5.088 | -5.77 | -3.738 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.133 | 0 | 0.216 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.398 | 0.191 | -0.661 | 0.517 | 0.445 | 1.281 | -0.067 | -0.018 | 0.089 | 0.299 | -0.201 | 0.215 | 0.082 | 0.058 | 0.189 | 0.311 | -0.026 | 0.23 |
| Income Before Tax
| -8.897 | -6.119 | -5.86 | -3.922 | -6.034 | -5.232 | -7.896 | -11.284 | -14.864 | -20.097 | -12.604 | 4.097 | -9.818 | -11.341 | -8.23 | -4.777 | -5.796 | -3.508 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.117 | 0 | 0.228 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 1.002 | 0 | -0.557 | -0.445 | -1.352 | 0.067 | 0.018 | -0.089 | 0.32 | 0.191 | -0.174 | 0.064 | -0.437 | -0.189 | -0.311 | 0.198 | 0.16 |
| Net Income
| -8.897 | -6.119 | -5.86 | -3.922 | -5.589 | -3.88 | -7.963 | -11.302 | -14.775 | -20.097 | -12.604 | 4.097 | -9.818 | -11.341 | -8.23 | -4.777 | -5.796 | -3.508 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.117 | 0 | 0.228 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.43 | -0.99 | -0.94 | -0.63 | -0.86 | -0.96 | -1.98 | -2.81 | -3.67 | -5.2 | -3.2 | 1.2 | -3.8 | -2.9 | -2.52 | -1.46 | -1.78 | -1.08 |
| EPS Diluted
| -1.43 | -0.99 | -0.94 | -0.63 | -0.86 | -0.96 | -1.98 | -2.81 | -3.67 | -5.2 | -3.2 | 1.2 | -3.8 | -2.9 | -2.52 | -1.46 | -1.78 | -1.08 |
| EBITDA
| -9.295 | -6.31 | -5.199 | -4.399 | -6.475 | -6.513 | -7.829 | -11.067 | -14.601 | -20.32 | -12.355 | 3.937 | -9.793 | -11.346 | -8.467 | -5.226 | -5.544 | -3.55 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.129 | 0 | 0.219 | 0 | 0 | 0 | 0 | 0 | 0 |